应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
PFE 辉瑞
未开盘 07-13 16:00:00 EDT
24.48
+0.31
+1.28%
盘后
24.51
+0.03
+0.12%
19:59 EDT
最高
24.72
最低
24.23
成交量
4,295万
今开
24.28
昨收
24.17
日振幅
2.03%
总市值
1,392亿
流通市值
1,382亿
总股本
56.86亿
成交额
10.52亿
换手率
0.76%
流通股本
56.44亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
BMO将默沙东目标价从135美元上调至142美元；将辉瑞目标股价从34美元下调至30美元。
智通财经 · 07-13 19:09
BMO将默沙东目标价从135美元上调至142美元；将辉瑞目标股价从34美元下调至30美元。
市场消息：美国FDA批准辉瑞Padcev联合Keytruda用于治疗肌层浸润性膀胱癌。
智通财经 · 07-10
市场消息：美国FDA批准辉瑞Padcev联合Keytruda用于治疗肌层浸润性膀胱癌。
美国FDA批准Padcev®联合Keytruda®作为肌层浸润性膀胱癌新辅助及辅助疗法，不限顺铂适用性
美股速递 · 07-10
美国FDA批准Padcev®联合Keytruda®作为肌层浸润性膀胱癌新辅助及辅助疗法，不限顺铂适用性
FDA批准帕博利珠单抗或帕博利珠单抗联合贝拉海藻糖酶Alfa-pmph，各自与恩福妥单抗Vedotin-ejfv联用，治疗肌层浸润性膀胱癌
美股速递 · 07-10
FDA批准帕博利珠单抗或帕博利珠单抗联合贝拉海藻糖酶Alfa-pmph，各自与恩福妥单抗Vedotin-ejfv联用，治疗肌层浸润性膀胱癌
美银：将辉瑞目标价下调至26美元
格隆汇 · 07-10
美银：将辉瑞目标价下调至26美元
平安好医生与辉瑞中国达成合作 持续探索“医药险患”融合路径
证券日报网 · 07-09
平安好医生与辉瑞中国达成合作 持续探索“医药险患”融合路径
小摩下调辉瑞目标价至28美元
格隆汇 · 07-09
小摩下调辉瑞目标价至28美元
强强联合！平安好医生(01833)携手辉瑞中国打造“医药险患”一体化融合新标杆
智通财经 · 07-07
强强联合！平安好医生(01833)携手辉瑞中国打造“医药险患”一体化融合新标杆
汇丰将辉瑞目标股价从32美元下调至28美元，将评级从买入下调至持有。
智通财经 · 07-06
汇丰将辉瑞目标股价从32美元下调至28美元，将评级从买入下调至持有。
辉瑞股价下跌1.4%。
智通财经 · 06-30
辉瑞股价下跌1.4%。
辉瑞加拿大公司：加拿大批准用于无法接受顺铂治疗的肌层浸润性膀胱癌患者的围手术期治疗方案
美股速递 · 06-29
辉瑞加拿大公司：加拿大批准用于无法接受顺铂治疗的肌层浸润性膀胱癌患者的围手术期治疗方案
辉瑞GLP-1药物通过中国医保药品目录初审
美股速递 · 06-29
辉瑞GLP-1药物通过中国医保药品目录初审
耐克挖角辉瑞CFO，助力公司推进转型重振投资者信心
智通财经 · 06-25
耐克挖角辉瑞CFO，助力公司推进转型重振投资者信心
维立志博-B完成B轮融资，辉瑞风投领投，Deep Track Capital、GV与Aditum Bio跟投
美股速递 · 06-25
维立志博-B完成B轮融资，辉瑞风投领投，Deep Track Capital、GV与Aditum Bio跟投
外商借链博会等国际展会加深布局中国市场
经济参考网 · 06-25
外商借链博会等国际展会加深布局中国市场
辉瑞：董事会批准每股 0.43 美元季度现金股息。
智通财经 · 06-25
辉瑞：董事会批准每股 0.43 美元季度现金股息。
异动解读｜辉瑞盘中下跌3.03%，核心肿瘤管线三期临床失利叠加高管离职持续承压
行情直击 · 06-25
异动解读｜辉瑞盘中下跌3.03%，核心肿瘤管线三期临床失利叠加高管离职持续承压
三期研究结果出炉：Sigvotatug Vedotin未能改善总生存期，盘后辉瑞股价应声下跌1%
美股速递 · 06-23
三期研究结果出炉：Sigvotatug Vedotin未能改善总生存期，盘后辉瑞股价应声下跌1%
辉瑞公布Sigvotatug Vedotin用于经治转移性非鳞状非小细胞肺癌的III期临床试验关键结果
美股速递 · 06-23
辉瑞公布Sigvotatug Vedotin用于经治转移性非鳞状非小细胞肺癌的III期临床试验关键结果
异动解读｜辉瑞盘中下跌3.03%，首席财务官官宣离职引发市场波动
行情直击 · 06-18
异动解读｜辉瑞盘中下跌3.03%，首席财务官官宣离职引发市场波动
暂无数据
公司概况
公司名称：
辉瑞
所属市场：
NYSE
上市日期：
--
主营业务：
辉瑞公司于1942年6月2日根据特拉华州法律成立。公司是一家以研究为基础的全球性生物制药公司。公司运用科学和全球资源，通过发现、开发、制造和分销保健产品（包括创新药物和疫苗），为人们带来延长和显著改善其生活的疗法。公司在发达国家和新兴市场开展工作，致力于促进健康、预防、治疗和治愈这个时代最令人恐惧的疾病。公司与医疗保健提供商、政府和当地社区合作，支持并扩大在全球范围内获得可靠、负担得起的医疗保健服务。
发行价格：
--
{"stockData":{"symbol":"PFE","market":"US","secType":"STK","nameCN":"辉瑞","latestPrice":24.48,"timestamp":1783972800000,"preClose":24.17,"halted":0,"volume":42953402,"hourTrading":{"tag":"盘后","latestPrice":24.51,"preClose":24.48,"latestTime":"19:59 EDT","volume":1173808,"amount":28731177.037,"timestamp":1783987199517,"change":0.03,"changeRate":0.001225,"amplitude":0.002855},"delay":0,"changeRate":0.012825817128671854,"floatShares":5644296476,"shares":5685707552,"eps":1.312648,"marketStatus":"未开盘","change":0.31,"latestTime":"07-13 16:00:00 EDT","open":24.28,"high":24.72,"low":24.23,"amount":1051678095.972526,"amplitude":0.020273,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.312648,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1784016000000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":-819144000000,"exchange":"NYSE","adjPreClose":24.17,"dividendRate":0.070298,"preHourTrading":{"tag":"盘前","latestPrice":24.25,"preClose":24.17,"latestTime":"09:29 EDT","volume":159955,"amount":3879560.0867600003,"timestamp":1783949396257,"change":0.08,"changeRate":0.00331,"amplitude":0.005743},"postHourTrading":{"tag":"盘后","latestPrice":24.51,"preClose":24.48,"latestTime":"19:59 EDT","volume":1173808,"amount":28731177.037,"timestamp":1783987199517,"change":0.03,"changeRate":0.001225,"amplitude":0.002855},"volumeRatio":1.087029,"optionData":{"bulkOrders":[{"symbol":"PFE","call":false,"expireDate":1789704000000,"strike":"25.0","timestamp":1783954830712,"price":1.32,"volume":3500,"amount":462000,"type":"+"},{"symbol":"PFE","call":false,"expireDate":1799989200000,"strike":"20.0","timestamp":1783969794583,"price":0.34,"volume":2000,"amount":68000,"type":"+"}]},"impliedVol":0.2403,"impliedVolPercentile":0.247},"requestUrl":"/m/hq/s/PFE/tweets","defaultTab":"tweets","newsList":[{"id":"2651157371","title":"BMO将默沙东目标价从135美元上调至142美元；将辉瑞目标股价从34美元下调至30美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2651157371","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651157371?lang=zh_cn&edition=full","pubTime":"2026-07-13 19:09","pubTimestamp":1783940941,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1989771016.USD","LU0965509283.SGD","SG9999003800.SGD","IE00B4R5TH58.HKD","LU0266013472.USD","FTXH","BK4588","SG9999014575.USD","LU2023250504.SGD","LU2491050154.USD","LU1066051811.HKD","IE00BJJMRZ35.SGD","LU1923622614.USD","LU1585245621.USD","LU0122379950.USD","LU0321505868.SGD","SG9999001176.SGD","LU1066051498.USD","LU1430594728.SGD","SG9999014559.SGD","LU0006306889.USD","LU0130102774.USD","LU0456855351.SGD","LU2023250843.SGD","IE00BJT1NW94.SGD","LU0477156953.USD","LU2433249047.HKD","FHLC","LU2125909247.SGD","IE0009355771.USD","SG9999015358.SGD","LU1883839398.USD","BK4534","LU2324357040.USD","LU1069347547.HKD","LU2361045086.USD","BK4581","SG9999002224.SGD","LU0868494708.USD","JDOC","LU2125909593.SGD","LU1061106388.HKD","IE00B1BXHZ80.USD","XLV","LU2491049909.HKD","IE00B2B36J28.USD","LU0859254822.USD","IE00B19Z3581.USD","SG9999014542.SGD","LU2125154778.USD","LU0265550359.USD","LU1057294990.SGD","BK4559","LU1941712348.USD","IE00BLSP4239.USD","BK4550","LU0289739699.SGD","IE00B3T34201.USD","LU1983299246.USD","LU0965509101.SGD","LU1929549753.HKD","LU1066053197.SGD","LU1093756325.SGD","IE00B19Z3B42.SGD","LU0965508806.USD","LU0238689110.USD","SG9999002232.USD","BK4007","BK4568","LU0306806265.USD","LU0321505439.SGD","IYH","IE00BFTCPJ56.SGD","LU2360032135.SGD","LU1989772923.USD","LU2112291526.USD","SG9999001440.SGD","LU0320765489.SGD","VHT","LU0985320562.USD","LU2357627491.SGD","LU1934455277.USD","BK4585","LU1934455863.HKD","LU2089984988.USD","LU0985481810.HKD","LU0203347892.USD","LU2468319806.SGD","LU0942090050.USD","LU0225284248.USD","BK4592","LU0861579265.USD","LU1571399168.USD","LU0965509010.AUD","IE00BLSP4452.SGD","LU1934455194.USD","LU1291159041.SGD","SG9999011175.SGD","IHE","LU1201861249.SGD","LU1974910355.USD","LU1894683348.USD","BK4599","BK4516","LU0432979614.USD","LU1116320901.HKD","LU1037948541.HKD","IE0002141913.USD","PPH","LU0208291251.USD","SG9999015341.SGD","OZEM","LU0868494617.USD","SG9999013999.USD","LU1023059063.AUD","LU0980610538.SGD","LU0203345920.USD","LU2596442595.SGD","LU1699723380.USD","IE00BSNM7G36.USD","IE00BBT3K403.USD","LU1035773651.USD","BMED","LU0648001328.SGD","LU1093756168.USD","LU0170899867.USD","LU2106854487.HKD","LU0130517989.USD","LU0098860793.USD","LU1066051225.USD","HRTS","IE000M9KFDE8.USD","SG9999014567.USD","LU0306807586.USD","SGXZ57979304.SGD","LU0070302665.USD","LU1037948897.HKD","LU2361044949.HKD","LU1989772840.SGD","LU0225771236.USD","LU0265550946.USD","LU2461242641.AUD","LU2361044865.SGD","PAWZ","BK4533","LU0320765646.SGD","LU1941712264.USD","IE00BN8TJ469.HKD","MRK","LU2491050071.SGD","LU0058720904.USD","LU0211331839.USD","LU1162221912.USD","PFE","LU1116320737.USD","SG9999001176.USD","GDOC","LU0234572021.USD","RXL","LU0106261372.USD","IE0002270589.USD","LU1917777945.USD","IXJ","LU1894683264.USD","LU2125154935.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650213980","title":"市场消息：美国FDA批准辉瑞Padcev联合Keytruda用于治疗肌层浸润性膀胱癌。","url":"https://stock-news.laohu8.com/highlight/detail?id=2650213980","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650213980?lang=zh_cn&edition=full","pubTime":"2026-07-10 23:26","pubTimestamp":1783697183,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0306806265.USD","LU0985481810.HKD","SG9999013999.USD","LU0122379950.USD","SG9999001176.USD","BK4588","IE00BLSP4452.SGD","BK4007","IE00BBT3K403.USD","IE00BLSP4239.USD","LU0868494617.USD","IE00B19Z3581.USD","SG9999003800.SGD","BK4550","BK4599","LU1066051498.USD","SG9999002232.USD","BK4534","SG9999011175.SGD","IE00B3T34201.USD","IE00B19Z3B42.SGD","OZEM","LU0058720904.USD","LU1066053197.SGD","SG9999001176.SGD","BK4581","BK4533","IE0002270589.USD","IE000M9KFDE8.USD","LU0225284248.USD","LU1894683264.USD","LU0289739699.SGD","LU2596442595.SGD","LU1894683348.USD","PFE","LU0170899867.USD","SG9999002224.SGD","LU0225771236.USD","BK4585","LU1883839398.USD","LU0321505439.SGD","LU0456855351.SGD","BK4592","LU0234572021.USD","LU1057294990.SGD","LU1023059063.AUD","SGXZ57979304.SGD","BK4568","LU0321505868.SGD","LU0306807586.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108884610","title":"美国FDA批准Padcev®联合Keytruda®作为肌层浸润性膀胱癌新辅助及辅助疗法，不限顺铂适用性","url":"https://stock-news.laohu8.com/highlight/detail?id=1108884610","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108884610?lang=zh_cn&edition=full","pubTime":"2026-07-10 23:25","pubTimestamp":1783697156,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局已批准将Padcev与Keytruda联合疗法，用于肌层浸润性膀胱癌患者的新辅助及辅助治疗。此项批准的关键在于，无论患者是否符合顺铂化疗的适用条件，均可使用该联合方案。此次批准基于关键的临床研究数据，显示了该联合疗法在目标患者群体中的显著疗效与可管理的安全性。随着监管绿灯的亮起，该方案有望迅速融入临床实践，为肌层浸润性膀胱癌患者提供新的重要治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0122379950.USD","LU1883839398.USD","IE0002270589.USD","BK4568","LU0170899867.USD","BK4592","BK4585","IE00B3T34201.USD","LU1894683264.USD","LU1057294990.SGD","IE00B19Z3581.USD","SG9999003800.SGD","SG9999011175.SGD","LU0225771236.USD","IE00BLSP4239.USD","SG9999013999.USD","LU0058720904.USD","LU0289739699.SGD","LU1023059063.AUD","IE00BBT3K403.USD","OZEM","LU0985481810.HKD","SGXZ57979304.SGD","LU2596442595.SGD","BK4550","LU0321505868.SGD","LU0306806265.USD","LU1066053197.SGD","PFE","IE00B19Z3B42.SGD","BK4534","LU1066051498.USD","BK4007","IE000M9KFDE8.USD","SG9999001176.SGD","SG9999002232.USD","LU0456855351.SGD","LU0868494617.USD","BK4533","SG9999001176.USD","LU0225284248.USD","BK4581","BK4588","IE00BLSP4452.SGD","LU0321505439.SGD","LU1894683348.USD","SG9999002224.SGD","LU0306807586.USD","LU0234572021.USD","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162268794","title":"FDA批准帕博利珠单抗或帕博利珠单抗联合贝拉海藻糖酶Alfa-pmph，各自与恩福妥单抗Vedotin-ejfv联用，治疗肌层浸润性膀胱癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1162268794","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162268794?lang=zh_cn&edition=full","pubTime":"2026-07-10 22:28","pubTimestamp":1783693688,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已批准帕博利珠单抗，或帕博利珠单抗联合贝拉海藻糖酶Alfa-pmph，各自与恩福妥单抗Vedotin-ejfv联用，用于治疗肌层浸润性膀胱癌。这一决定为患者提供了一种新的联合治疗方案选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0456855351.SGD","LU0965509010.AUD","LU2491050154.USD","LU2361044865.SGD","LU0211331839.USD","FHLC","IE0009355771.USD","LU0122379950.USD","SG9999013999.USD","LU1894683348.USD","LU1093756168.USD","LU1923622614.USD","BK4568","IE00BJJMRZ35.SGD","IE00B1BXHZ80.USD","BK4516","LU0130102774.USD","LU0306806265.USD","LU0306807586.USD","LU1061106388.HKD","LU1162221912.USD","IE00B19Z3B42.SGD","BK4533","LU0265550359.USD","LU0965509101.SGD","SG9999002232.USD","LU1917777945.USD","LU2125154778.USD","LU2023250843.SGD","OZEM","LU1116320901.HKD","LU2089984988.USD","LU2106854487.HKD","VHT","GDOC","IE00BFTCPJ56.SGD","LU1201861249.SGD","LU1066051811.HKD","LU0859254822.USD","SG9999014559.SGD","LU0868494708.USD","LU0289739699.SGD","SG9999011175.SGD","LU2125909593.SGD","LU1983299246.USD","XLV","BK4592","LU1989772923.USD","IE00B2B36J28.USD","IE000M9KFDE8.USD","BK4007","LU1037948897.HKD","IE0002141913.USD","LU1093756325.SGD","LU0070302665.USD","IE00B4R5TH58.HKD","LU0648001328.SGD","LU1057294990.SGD","LU1941712348.USD","IE00BLSP4239.USD","LU1430594728.SGD","LU2491050071.SGD","PPH","LU0320765646.SGD","LU2023250504.SGD","BK4534","IYH","SG9999003800.SGD","SG9999015358.SGD","IHE","IE00BLSP4452.SGD","BK4581","BK4559","SG9999001176.USD","IE00BN8TJ469.HKD","JDOC","LU0942090050.USD","LU2125154935.USD","IE00BBT3K403.USD","LU1571399168.USD","SG9999001176.SGD","LU1585245621.USD","LU1066051498.USD","LU2361045086.USD","LU0130517989.USD","LU0203347892.USD","LU0868494617.USD","LU1934455863.HKD","LU1894683264.USD","SG9999002224.SGD","LU0477156953.USD","BK4585","PFE","IE00B3T34201.USD","LU0238689110.USD","LU2461242641.AUD","LU0225284248.USD","LU2360032135.SGD","IXJ","LU0225771236.USD","LU1066051225.USD","LU0965508806.USD","LU0170899867.USD","BK4599","LU2357627491.SGD","IE0002270589.USD","LU1037948541.HKD","HRTS","LU1989772840.SGD","LU1291159041.SGD","LU1116320737.USD","IE00B19Z3581.USD","LU0985320562.USD","LU2361044949.HKD","LU1934455194.USD","LU0321505439.SGD","LU0234572021.USD","LU2468319806.SGD","IE00BSNM7G36.USD","LU2125909247.SGD","SG9999015341.SGD","BMED","LU0861579265.USD","LU1035773651.USD","SG9999001440.SGD","LU1989771016.USD","LU0208291251.USD","LU0098860793.USD","LU0432979614.USD","LU1883839398.USD","IE00BJT1NW94.SGD","LU1929549753.HKD","BK4588","LU1974910355.USD","LU2324357040.USD","LU0266013472.USD","LU1066053197.SGD","LU2433249047.HKD","SGXZ57979304.SGD","LU2491049909.HKD","LU0058720904.USD","LU0965509283.SGD","SG9999014542.SGD","LU0321505868.SGD","LU0203345920.USD","LU0320765489.SGD","SG9999014567.USD","LU0265550946.USD","RXL","SG9999014575.USD","LU1699723380.USD","MRK","LU1023059063.AUD","LU0980610538.SGD","LU1069347547.HKD","LU2112291526.USD","LU1934455277.USD","BK4550","LU0985481810.HKD","LU1941712264.USD","LU0106261372.USD","LU0006306889.USD","PAWZ","LU2596442595.SGD","FTXH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650413133","title":"美银：将辉瑞目标价下调至26美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2650413133","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650413133?lang=zh_cn&edition=full","pubTime":"2026-07-10 21:55","pubTimestamp":1783691724,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["SGXZ57979304.SGD","IE000M9KFDE8.USD","BK4007","IE00B19Z3B42.SGD","OZEM","LU0225284248.USD","LU0456855351.SGD","BK4533","LU0122379950.USD","IE0002270589.USD","LU0289739699.SGD","IE00BLSP4452.SGD","BK4588","LU1883839398.USD","PFE","SG9999002224.SGD","LU0321505439.SGD","BK4581","LU0306806265.USD","SG9999011175.SGD","LU1057294990.SGD","BK4550","LU0868494617.USD","BK4568","LU1894683348.USD","LU0985481810.HKD","IE00BLSP4239.USD","BK4534","BK4592","LU0306807586.USD","LU1023059063.AUD","LU1066051498.USD","LU1066053197.SGD","SG9999001176.USD","SG9999013999.USD","LU0225771236.USD","LU0234572021.USD","BK4599","SG9999003800.SGD","LU0321505868.SGD","SG9999001176.SGD","IE00B19Z3581.USD","IE00BBT3K403.USD","SG9999002232.USD","IE00B3T34201.USD","LU0170899867.USD","LU0058720904.USD","LU2596442595.SGD","BK4585","LU1894683264.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650927491","title":"平安好医生与辉瑞中国达成合作 持续探索“医药险患”融合路径","url":"https://stock-news.laohu8.com/highlight/detail?id=2650927491","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650927491?lang=zh_cn&edition=full","pubTime":"2026-07-09 21:47","pubTimestamp":1783604820,"startTime":"0","endTime":"0","summary":"本报讯 近日，平安健康医疗科技有限公司宣布与辉瑞投资有限公司达成深度合作，双方将共同打造“医药险商业闭环”与“医药患全病程管理”双闭环体系，持续探索医、药、险、患融合路径。据悉，双方还将持续围绕肿瘤、罕见病、疫苗及代谢健康等领域展开合作探索。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/hk/2026-07-09/doc-inihfpqx5264182.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-07-09/doc-inihfpqx5264182.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4581","LU0321505439.SGD","SG9999001176.USD","SG9999002232.USD","LU1023059063.AUD","SG9999003800.SGD","BK4585","SG9999001176.SGD","LU0122379950.USD","LU0985481810.HKD","BK1142","LU1066051498.USD","BK1571","BK4007","BK4588","BK4550","BK1219","IE00BBT3K403.USD","LU0456855351.SGD","LU0058720904.USD","LU0306806265.USD","LU0306807586.USD","IE00B19Z3B42.SGD","LU1883839398.USD","PFE","BK1247","BK4568","IE000M9KFDE8.USD","LU1057294990.SGD","SG9999002224.SGD","IE00BLSP4239.USD","SG9999013999.USD","IE00B19Z3581.USD","01833","BK1617","LU0868494617.USD","IE00BLSP4452.SGD","LU2596442595.SGD","BK4599","LU0225771236.USD","BK4534","SG9999011175.SGD","BK1615","LU1894683348.USD","IE0002270589.USD","BK4592","SGXZ57979304.SGD","LU1894683264.USD","OZEM","LU0289739699.SGD","IE00B3T34201.USD","LU0234572021.USD","BK1515","LU0225284248.USD","LU0321505868.SGD","LU1066053197.SGD","BK4533","LU0170899867.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650948115","title":"小摩下调辉瑞目标价至28美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2650948115","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650948115?lang=zh_cn&edition=full","pubTime":"2026-07-09 11:23","pubTimestamp":1783567411,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0985481810.HKD","IE0002270589.USD","LU0456855351.SGD","LU0321505439.SGD","IE000M9KFDE8.USD","LU0170899867.USD","OZEM","LU1894683264.USD","PFE","IE00B19Z3581.USD","LU1894683348.USD","BK4592","SG9999013999.USD","LU1023059063.AUD","LU1883839398.USD","BK4599","IE00BLSP4239.USD","BK4533","LU0225284248.USD","BK4581","LU0058720904.USD","LU0306807586.USD","SG9999011175.SGD","IE00B19Z3B42.SGD","BK4568","LU2596442595.SGD","LU1066053197.SGD","LU0306806265.USD","BK4007","IE00BLSP4452.SGD","BK4585","BK4588","LU0234572021.USD","LU0868494617.USD","BK4534","SG9999001176.SGD","SGXZ57979304.SGD","LU0321505868.SGD","SG9999002224.SGD","SG9999001176.USD","SG9999003800.SGD","IE00B3T34201.USD","LU1066051498.USD","BK4550","LU1057294990.SGD","SG9999002232.USD","LU0289739699.SGD","IE00BBT3K403.USD","LU0122379950.USD","LU0225771236.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649600387","title":"强强联合！平安好医生(01833)携手辉瑞中国打造“医药险患”一体化融合新标杆","url":"https://stock-news.laohu8.com/highlight/detail?id=2649600387","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649600387?lang=zh_cn&edition=full","pubTime":"2026-07-07 16:05","pubTimestamp":1783411506,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，2026年7月7日，平安好医生与辉瑞中国达成深度合作，依托平安医健服务、商保支付、企业健康管理服务、AI医疗、全病程管理与亿级用户底盘，结合辉瑞在创新药研发、循证医学等领域的优势，双方将共同打造“医药险商业闭环”与“医药患全病程管理”双闭环体系，树立国内医、药、险、患一体化融合标杆。平安好医生CEO何明科表示，医药险深度融合是互联网医疗核心发展方向。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1464043.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","LU0234572021.USD","LU1894683264.USD","BK1161","SG9999001176.USD","SG9999002232.USD","LU1023059063.AUD","SG9999013999.USD","IE00BLSP4452.SGD","PFE","BK1615","BK1219","LU0868494617.USD","BK1617","BK4550","IE000M9KFDE8.USD","LU0321505868.SGD","LU1883839398.USD","LU2596442595.SGD","LU1057294990.SGD","BK1247","BK1142","IE00B3T34201.USD","BK1571","SG9999011175.SGD","IE00BBT3K403.USD","IE0002270589.USD","BK4588","LU0122379950.USD","IE00B19Z3581.USD","LU0306807586.USD","LU0225284248.USD","SG9999003800.SGD","SG9999001176.SGD","LU0170899867.USD","BK4599","LU0321505439.SGD","SGXZ57979304.SGD","BK4533","159938","BK4592","LU1066051498.USD","LU0289739699.SGD","LU0058720904.USD","OZEM","IE00BLSP4239.USD","09939","BK4585","IE00B19Z3B42.SGD","01833"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649643195","title":"汇丰将辉瑞目标股价从32美元下调至28美元，将评级从买入下调至持有。","url":"https://stock-news.laohu8.com/highlight/detail?id=2649643195","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649643195?lang=zh_cn&edition=full","pubTime":"2026-07-06 13:19","pubTimestamp":1783315199,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["SGXZ57979304.SGD","SG9999003800.SGD","IE00B19Z3581.USD","LU1057294990.SGD","IE00BLSP4452.SGD","BK4588","LU0225771236.USD","SG9999011175.SGD","IE00BLSP4239.USD","BK4550","LU0289739699.SGD","LU1894683348.USD","IE00B3T34201.USD","BK4599","LU0122379950.USD","LU0321505868.SGD","SG9999001176.SGD","LU1066051498.USD","LU1066053197.SGD","BK4533","LU0456855351.SGD","IE00B19Z3B42.SGD","SG9999002232.USD","BK4007","BK4568","LU0306806265.USD","LU0321505439.SGD","LU0058720904.USD","LU1883839398.USD","OZEM","BK4534","LU0868494617.USD","SG9999013999.USD","BK4581","LU1023059063.AUD","PFE","LU2596442595.SGD","SG9999001176.USD","IE00BBT3K403.USD","SG9999002224.SGD","LU0234572021.USD","LU0170899867.USD","BK4585","LU0985481810.HKD","IE0002270589.USD","LU0306807586.USD","IE000M9KFDE8.USD","LU0225284248.USD","LU1894683264.USD","BK4592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647955270","title":"辉瑞股价下跌1.4%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2647955270","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647955270?lang=zh_cn&edition=full","pubTime":"2026-06-30 22:42","pubTimestamp":1782830532,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["SG9999001176.USD","BK4585","BK4533","SG9999002232.USD","IE000M9KFDE8.USD","LU2596442595.SGD","LU0306806265.USD","BK4568","LU1894683348.USD","SGXZ57979304.SGD","BK4599","BK4550","SG9999011175.SGD","PFE","IE00BLSP4239.USD","LU0456855351.SGD","LU0985481810.HKD","IE00B19Z3B42.SGD","BK4588","BK4534","BK4007","LU0306807586.USD","LU0058720904.USD","LU1894683264.USD","IE00BLSP4452.SGD","IE00B3T34201.USD","LU0170899867.USD","IE0002270589.USD","LU0321505439.SGD","LU0225771236.USD","BK4581","IE00BBT3K403.USD","LU0321505868.SGD","SG9999001176.SGD","LU1883839398.USD","LU0122379950.USD","SG9999013999.USD","IE00B19Z3581.USD","LU1066053197.SGD","SG9999002224.SGD","LU1066051498.USD","SG9999003800.SGD","LU1057294990.SGD","LU0225284248.USD","LU0234572021.USD","LU1023059063.AUD","LU0289739699.SGD","BK4592","LU0868494617.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182051396","title":"辉瑞加拿大公司：加拿大批准用于无法接受顺铂治疗的肌层浸润性膀胱癌患者的围手术期治疗方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1182051396","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182051396?lang=zh_cn&edition=full","pubTime":"2026-06-29 21:08","pubTimestamp":1782738510,"startTime":"0","endTime":"0","summary":"加拿大监管机构已批准一种新的围手术期治疗方案，适用于无法耐受顺铂基础疗法的肌层浸润性膀胱癌患者。这一进展为这部分患者群体提供了重要的临床选择。该方案旨在在手术前后辅助治疗，以改善治疗效果。对于因身体状况无法接受标准含顺铂化疗的患者而言，此次批准意味着治疗路径的拓宽。这一决定有望影响加拿大的临床实践指南，并为类似患者群体带来新的希望。医疗专业人士可将此方案纳入综合治疗策略中，以优化患者的长期预后。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999001176.USD","IE00B19Z3B42.SGD","LU0306806265.USD","BK4585","LU0456855351.SGD","BK4568","IE00BBT3K403.USD","SGXZ57979304.SGD","LU0058720904.USD","SG9999001176.SGD","BK4534","BK4581","BK4007","LU0225771236.USD","LU0234572021.USD","LU0868494617.USD","SG9999002232.USD","LU0321505868.SGD","IE00BLSP4239.USD","BK4588","BK4592","BK4599","LU0289739699.SGD","LU0225284248.USD","LU1057294990.SGD","SG9999003800.SGD","LU0321505439.SGD","LU1894683348.USD","PFE","SG9999013999.USD","IE00B3T34201.USD","LU0985481810.HKD","LU0122379950.USD","SG9999002224.SGD","IE00B19Z3581.USD","BK4550","LU0306807586.USD","IE00BLSP4452.SGD","LU1023059063.AUD","LU1066053197.SGD","BK4533","LU1066051498.USD","LU1883839398.USD","SG9999011175.SGD","IE000M9KFDE8.USD","LU2596442595.SGD","LU1894683264.USD","LU0170899867.USD","IE0002270589.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148306462","title":"辉瑞GLP-1药物通过中国医保药品目录初审","url":"https://stock-news.laohu8.com/highlight/detail?id=1148306462","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148306462?lang=zh_cn&edition=full","pubTime":"2026-06-29 13:01","pubTimestamp":1782709312,"startTime":"0","endTime":"0","summary":"辉瑞公司研发的一款GLP-1类药物，已成功通过中国国家医保药品目录的初步形式审查。根据官方发布的声明，这一进展标志着该药物在纳入国家基本医疗保险报销体系的过程中迈出了关键一步。\n药物通过初审，意味着其相关资料符合申报要求，获得了进入后续专家评审等环节的资格。最终能否被正式纳入医保目录，将取决于其临床价值、患者需求、以及医保基金承受能力等多方面的综合评估。\n这一消息受到市场密切关注。GLP-1类药物在治疗糖尿病和肥胖症等领域展现出显著疗效，全球市场需求旺盛。若辉瑞的该款药物最终成功进入中国医保目录，将有望提升其在中国市场的可及性与竞争力，惠及更广泛的患者群体。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4550","LU0306807586.USD","LU0234572021.USD","SG9999003800.SGD","BK4568","BK4592","BK4588","IE000M9KFDE8.USD","LU0306806265.USD","BK4534","LU1057294990.SGD","LU1066053197.SGD","LU0321505439.SGD","IE00BBT3K403.USD","LU1883839398.USD","PFE","LU0122379950.USD","LU0058720904.USD","IE00BLSP4452.SGD","LU0225771236.USD","SG9999001176.USD","LU2596442595.SGD","LU1066051498.USD","IE00B19Z3B42.SGD","IE00B3T34201.USD","IE00BLSP4239.USD","LU1894683264.USD","IE00B19Z3581.USD","LU0868494617.USD","LU0456855351.SGD","LU0321505868.SGD","LU1023059063.AUD","BK4533","LU0289739699.SGD","IE0002270589.USD","BK4599","LU0170899867.USD","LU1894683348.USD","SGXZ57979304.SGD","BK4581","LU0225284248.USD","SG9999001176.SGD","SG9999002224.SGD","LU0985481810.HKD","BK4585","SG9999002232.USD","SG9999011175.SGD","SG9999013999.USD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646022801","title":"耐克挖角辉瑞CFO，助力公司推进转型重振投资者信心","url":"https://stock-news.laohu8.com/highlight/detail?id=2646022801","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646022801?lang=zh_cn&edition=full","pubTime":"2026-06-25 23:20","pubTimestamp":1782400836,"startTime":"0","endTime":"0","summary":"此次人事调整正值耐克面临转型压力之际。根据耐克公告，Denton于2022年加入辉瑞担任CFO，此前曾在家居零售商劳氏和医疗健康企业西维斯健康担任财务高管，拥有丰富的大型跨国企业财务管理经验。市场人士认为，新任CFO未来如何推动盈利改善、提升运营效率以及恢复投资者信心，将成为耐克下一阶段转型成败的重要观察指标。","market":"sh","thumbnail":"https://static.tigerbbs.com/68ab55b396d2dcbb09b0c2d9d4f9ce61","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/68ab55b396d2dcbb09b0c2d9d4f9ce61"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1459084.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0122379950.USD","LU1883839398.USD","IE0002270589.USD","BK4568","LU0170899867.USD","BK4592","BK4585","IE00B3T34201.USD","LU1894683264.USD","IE00BFXG0V08.USD","LU0708994859.HKD","NKE","LU0310800379.SGD","IE00BYQQ9H92.USD","LU1057294990.SGD","IE00B19Z3581.USD","LU0786609619.USD","SG9999003800.SGD","SG9999011175.SGD","LU0225771236.USD","BK4566","IE00BLSP4239.USD","SG9999013999.USD","LU0058720904.USD","LU0289739699.SGD","LU1023059063.AUD","BK4561","IE00BBT3K403.USD","LU0985481810.HKD","LU0128525689.USD","SGXZ57979304.SGD","LU2596442595.SGD","BK4550","LU2098885051.SGD","LU1303367103.USD","LU0321505868.SGD","LU0306806265.USD","LU0128525929.USD","LU1066053197.SGD","IE00B19Z3B42.SGD","LU1267930813.SGD","PFE","LU1267930227.SGD","BK4534","LU0310800965.SGD","LU0792757196.USD","LU1066051498.USD","LU0889566641.SGD","BK4007","IE000M9KFDE8.USD","LU0029864427.USD","SG9999001176.SGD","SG9999002224.SGD","SG9999002232.USD","LU0052756011.USD","LU0823411888.USD","BK4146","LU0456855351.SGD","BK4558","LU0868494617.USD","BK4533","SG9999001176.USD","LU0225284248.USD","BK4581","BK4588","IE00BLSP4452.SGD","LU0321505439.SGD","LU1894683348.USD","LU1267930573.SGD","LU0306807586.USD","LU0234572021.USD","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195591415","title":"维立志博-B完成B轮融资，辉瑞风投领投，Deep Track Capital、GV与Aditum Bio跟投","url":"https://stock-news.laohu8.com/highlight/detail?id=1195591415","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195591415?lang=zh_cn&edition=full","pubTime":"2026-06-25 18:42","pubTimestamp":1782384143,"startTime":"0","endTime":"0","summary":"南京维立志博生物科技有限公司近日成功完成B轮融资。本轮融资由辉瑞旗下的风险投资部门辉瑞风投领投，Deep Track Capital、GV以及Aditum Bio共同参与投资。维立志博-B是一家专注于肿瘤免疫治疗及自身免疫性疾病领域创新抗体药物研发的生物技术公司。辉瑞风投的领投，结合Deep Track Capital、GV和Aditum Bio等专业投资机构的共同参与，彰显了资本市场对维立志博-B研发平台与技术潜力的高度认可。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999013999.USD","IE00B19Z3581.USD","SG9999002224.SGD","IE0002270589.USD","LU0321505868.SGD","LU0122379950.USD","LU0234572021.USD","BK1161","BK4588","LU0456855351.SGD","LU1057294990.SGD","SG9999003800.SGD","LU1894683264.USD","LU0868494617.USD","LU1883839398.USD","09887","SG9999002232.USD","LU0306807586.USD","LU1066051498.USD","LU0058720904.USD","LU0321505439.SGD","LU1023059063.AUD","BK4007","LU1066053197.SGD","SG9999011175.SGD","HK0000252152.HKD","HK0000500386.USD","BK4592","LU0225284248.USD","IE00B3T34201.USD","IE00BBT3K403.USD","PFE","SG9999001176.SGD","SGXZ57979304.SGD","IE000M9KFDE8.USD","BK4550","IE00B19Z3B42.SGD","LU0985481810.HKD","BK4533","BK4568","IE00BLSP4239.USD","LU0225771236.USD","IE00BLSP4452.SGD","LU0289739699.SGD","BK4599","BK4581","BK4585","HK0000252160.HKD","LU0170899867.USD","SG9999001176.USD","LU0306806265.USD","LU1894683348.USD","BK4534","LU2596442595.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646753888","title":"外商借链博会等国际展会加深布局中国市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2646753888","media":"经济参考网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646753888?lang=zh_cn&edition=full","pubTime":"2026-06-25 16:43","pubTimestamp":1782377026,"startTime":"0","endTime":"0","summary":"在日前于北京举行的第四届中国国际供应链促进博览会(以下简称“链博会”)和多场国际级行业会议上，多国外商积极参与，不仅丰富了产业链资源、加强了供应链韧性，还纷纷通过推出创新服务和产品加深布局中国市场。松下控股株式会社执行董事、集团中国东北亚总代表中山正春对记者表示，公司连续多届参与链博会，对接触产业和市场非常有益。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606253783107245.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0122379950.USD","LU0823426480.USD","LU0058720904.USD","BK4534","LU0320764755.SGD","HK0000320223.HKD","LU0359201612.USD","LU0348825331.USD","LU2596442595.SGD","SG9999002232.USD","LU0708994859.HKD","LU1515016050.SGD","YUMC","LU0823426308.USD","LU0321505439.SGD","BK4504","BK4526","BK4581","IE0034224299.USD","LU0417516902.SGD","LU0029864427.USD","LU0289739699.SGD","LU1023059063.AUD","BK4568","LU2177674079.SGD","IE0003895053.USD","BK4550","IE00B19Z3581.USD","IE00BLSP4452.SGD","LU0310800379.SGD","SG9999003800.SGD","LU0128525929.USD","LU0228659784.USD","LU1267930573.SGD","BK4007","LU0672654166.SGD","BK4209","BK4585","IE00BLSP4239.USD","LU0327786744.USD","LU1051768304.USD","LU0234572021.USD","SG9999001176.USD","LU2008162690.USD","LU0306806265.USD","LU0651946864.USD","LU0868494617.USD","BK4531","HK0000320264.USD","IE00BBT3K403.USD","LU0359202008.SGD","LU0170899867.USD","SG9999013999.USD","LU1894683348.USD","LU0456842615.SGD","SG9999002224.SGD","LU0128522157.USD","BK4592","LU1057294990.SGD","HK0000306685.HKD","IE00B3T34201.USD","LU0225771236.USD","LU0306807586.USD","SG9999011175.SGD","LU0572944931.SGD","LU1023057109.AUD","BK4533","LU1894683264.USD","LU0650527681.SGD","LU0431992006.USD","IE000M9KFDE8.USD","PFE","SG9999001176.SGD","LU1883839398.USD","LU0456855351.SGD","LU0594300419.USD","BK0210","LU0321505868.SGD","IE00B0JY6N72.USD","BK4599","HK0000306701.USD","IE0002270589.USD","IE00BGV7N243.SGD","300795","LU0985481810.HKD","09987","IE00B19Z3B42.SGD","SGXZ57979304.SGD","LU2279701549.SGD","BK4588","LU1066051498.USD","LU0543330483.HKD","LU0868486357.SGD","LU0029875118.USD","LU0225284248.USD","LU1066053197.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646250843","title":"辉瑞：董事会批准每股 0.43 美元季度现金股息。","url":"https://stock-news.laohu8.com/highlight/detail?id=2646250843","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646250843?lang=zh_cn&edition=full","pubTime":"2026-06-25 03:55","pubTimestamp":1782330927,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4585","LU1066053197.SGD","LU0868494617.USD","IE00B19Z3581.USD","SG9999002232.USD","LU0306807586.USD","IE000M9KFDE8.USD","LU0170899867.USD","IE00BLSP4452.SGD","BK4592","LU1883839398.USD","LU1894683264.USD","SG9999013999.USD","SGXZ57979304.SGD","LU0456855351.SGD","SG9999002224.SGD","IE00BLSP4239.USD","LU0289739699.SGD","LU0122379950.USD","LU0985481810.HKD","BK4581","SG9999003800.SGD","LU0306806265.USD","LU1023059063.AUD","BK4533","BK4534","LU0234572021.USD","BK4599","LU0225284248.USD","IE0002270589.USD","SG9999001176.USD","LU0321505868.SGD","LU0058720904.USD","LU0225771236.USD","BK4568","LU2596442595.SGD","IE00BBT3K403.USD","IE00B3T34201.USD","LU1057294990.SGD","SG9999011175.SGD","LU1066051498.USD","BK4550","PFE","LU1894683348.USD","SG9999001176.SGD","IE00B19Z3B42.SGD","LU0321505439.SGD","BK4007","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136844385","title":"异动解读｜辉瑞盘中下跌3.03%，核心肿瘤管线三期临床失利叠加高管离职持续承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1136844385","media":"行情直击","labels":["executive","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136844385?lang=zh_cn&edition=full","pubTime":"2026-06-25 01:36","pubTimestamp":1782322610,"startTime":"0","endTime":"0","summary":"6月24日，辉瑞盘中下跌3.03%，报23.97美元/股，成交额10.23亿美元。消息面上，辉瑞近期利空因素密集释放。公司核心肿瘤管线药物Sigvotatug Vedotin三期临床试验结果显示未能显著改善患者总生存期，对公司寄予厚望的肿瘤领域布局构成明显打击，市场对其未来收入潜力进行重新评估。公司虽重申了财年指引，但未能提振市场信心，多重利空叠加下辉瑞持续走弱。辉瑞所在的制药行业中，礼来跌0.49%，诺华跌0.25%，强生跌0.05%，默沙东涨0.62%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161578237","title":"三期研究结果出炉：Sigvotatug Vedotin未能改善总生存期，盘后辉瑞股价应声下跌1%","url":"https://stock-news.laohu8.com/highlight/detail?id=1161578237","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161578237?lang=zh_cn&edition=full","pubTime":"2026-06-23 04:41","pubTimestamp":1782160897,"startTime":"0","endTime":"0","summary":"辉瑞公司股价在盘后交易中下跌了1%。此前，该公司公布了其药物Sigvotatug Vedotin的三期临床试验结果，数据显示该药物未能显著改善患者的总体生存期。\n这一结果对辉瑞寄予厚望的肿瘤管线构成了打击。市场迅速对此消息做出了反应，投资者信心受到考验。股价的波动反映了市场对研发进展的高度敏感，以及对未来收入潜力的重新评估。\n尽管遭遇挫折，辉瑞的总体研发管线依然庞大。公司表示将继续推进其他在研项目。然而，此次关键研究的失利无疑为相关领域的竞争格局增添了变数，也凸显了新药开发固有的高风险性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","SGXZ57979304.SGD","LU1057294990.SGD","IE000M9KFDE8.USD","LU0321505868.SGD","LU0456855351.SGD","LU0234572021.USD","LU1066051498.USD","SG9999002232.USD","LU0868494617.USD","BK4534","LU1066053197.SGD","LU0306807586.USD","LU1023059063.AUD","LU0306806265.USD","BK4550","IE00B3T34201.USD","LU1894683348.USD","BK4588","BK4585","IE00B19Z3581.USD","IE00B19Z3B42.SGD","LU0289739699.SGD","SG9999001176.SGD","SG9999002224.SGD","BK4007","IE0002270589.USD","PFE","LU1894683264.USD","LU0170899867.USD","LU0058720904.USD","IE00BLSP4239.USD","IE00BBT3K403.USD","SG9999011175.SGD","LU0321505439.SGD","SG9999013999.USD","LU0225771236.USD","BK4533","BK4592","LU0985481810.HKD","SG9999003800.SGD","LU2596442595.SGD","LU1883839398.USD","SG9999001176.USD","BK4599","LU0225284248.USD","LU0122379950.USD","IE00BLSP4452.SGD","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128127312","title":"辉瑞公布Sigvotatug Vedotin用于经治转移性非鳞状非小细胞肺癌的III期临床试验关键结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1128127312","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128127312?lang=zh_cn&edition=full","pubTime":"2026-06-23 04:30","pubTimestamp":1782160254,"startTime":"0","endTime":"0","summary":"辉瑞公司宣布，其候选药物Sigvotatug Vedotin在针对既往接受过治疗的转移性非鳞状非小细胞肺癌患者的III期临床试验中，已获得关键性顶线结果。该消息标志着该药物在这一难治性癌症适应症开发进程中的重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4550","LU0306807586.USD","LU0234572021.USD","SG9999003800.SGD","BK4568","BK4592","BK4588","IE000M9KFDE8.USD","LU0306806265.USD","BK4534","LU1057294990.SGD","LU1066053197.SGD","LU0321505439.SGD","IE00BBT3K403.USD","LU1883839398.USD","PFE","LU0122379950.USD","LU0058720904.USD","IE00BLSP4452.SGD","LU0225771236.USD","SG9999001176.USD","LU2596442595.SGD","LU1066051498.USD","IE00B19Z3B42.SGD","IE00B3T34201.USD","IE00BLSP4239.USD","LU1894683264.USD","IE00B19Z3581.USD","LU0868494617.USD","LU0456855351.SGD","LU0321505868.SGD","LU1023059063.AUD","BK4533","LU0289739699.SGD","IE0002270589.USD","BK4599","LU0170899867.USD","LU1894683348.USD","SGXZ57979304.SGD","BK4581","LU0225284248.USD","SG9999001176.SGD","SG9999002224.SGD","LU0985481810.HKD","BK4585","SG9999002232.USD","SG9999011175.SGD","SG9999013999.USD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149924240","title":"异动解读｜辉瑞盘中下跌3.03%，首席财务官官宣离职引发市场波动","url":"https://stock-news.laohu8.com/highlight/detail?id=1149924240","media":"行情直击","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149924240?lang=zh_cn&edition=full","pubTime":"2026-06-18 22:24","pubTimestamp":1781792699,"startTime":"0","endTime":"0","summary":"6月18日，辉瑞盘中下跌3.03%，报25.115美元/股，成交额5.49亿美元。消息面上，辉瑞披露高管人事变动公告，公司首席财务官戴夫·丹顿将于8月15日正式离职，后续将转战消费品行业发展。公司已任命Cecile Guegan为临时首席财务官。丹顿于2022年加入辉瑞执掌财务运营工作，入职前曾历任劳氏、CVS Health首席财务官，具备丰富的大型企业财务管控经验。核心高管突然离任加剧了市场对公司管理层稳定性的担忧，叠加制药板块整体承压，辉瑞股价明显走弱。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFE"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pfizer.com","stockEarnings":[{"period":"1week","weight":0.032},{"period":"1month","weight":-0.066},{"period":"3month","weight":-0.097},{"period":"6month","weight":-0.043},{"period":"1year","weight":-0.0456},{"period":"ytd","weight":-0.0169}],"compareEarnings":[{"period":"1week","weight":-0.0028},{"period":"1month","weight":0.01},{"period":"3month","weight":0.0788},{"period":"6month","weight":0.0852},{"period":"1year","weight":0.2013},{"period":"ytd","weight":0.0986}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"辉瑞公司于1942年6月2日根据特拉华州法律成立。公司是一家以研究为基础的全球性生物制药公司。公司运用科学和全球资源，通过发现、开发、制造和分销保健产品（包括创新药物和疫苗），为人们带来延长和显著改善其生活的疗法。公司在发达国家和新兴市场开展工作，致力于促进健康、预防、治疗和治愈这个时代最令人恐惧的疾病。公司与医疗保健提供商、政府和当地社区合作，支持并扩大在全球范围内获得可靠、负担得起的医疗保健服务。","yearOnYearQuotes":[{"month":1,"riseRate":0.456522,"avgChangeRate":0.002542},{"month":2,"riseRate":0.456522,"avgChangeRate":-0.005934},{"month":3,"riseRate":0.608696,"avgChangeRate":0.014732},{"month":4,"riseRate":0.574468,"avgChangeRate":0.016819},{"month":5,"riseRate":0.489362,"avgChangeRate":0.007168},{"month":6,"riseRate":0.489362,"avgChangeRate":0.001032},{"month":7,"riseRate":0.489362,"avgChangeRate":0.011469},{"month":8,"riseRate":0.456522,"avgChangeRate":0.0002},{"month":9,"riseRate":0.456522,"avgChangeRate":0.004432},{"month":10,"riseRate":0.630435,"avgChangeRate":0.013042},{"month":11,"riseRate":0.695652,"avgChangeRate":0.028255},{"month":12,"riseRate":0.5,"avgChangeRate":0.008452}],"exchange":"NYSE","name":"辉瑞","nameEN":"Pfizer"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"辉瑞(PFE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供辉瑞(PFE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"辉瑞,PFE,辉瑞股票,辉瑞股票老虎,辉瑞股票老虎国际,辉瑞行情,辉瑞股票行情,辉瑞股价,辉瑞股市,辉瑞股票价格,辉瑞股票交易,辉瑞股票购买,辉瑞股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"辉瑞(PFE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供辉瑞(PFE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}